Open Access Repository

Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region


Downloads per month over past year

Salmasi, S, Lee, KS, Ming, LC ORCID: 0000-0002-6971-1383, Neoh, CF, Elrggal, ME, Babar, ZD, Khan, TM and Hadi, MA 2017 , 'Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region' , BMC Cancer, vol. 17, no. 1 , pp. 1-11 , doi: 10.1186/s12885-017-3888-y.

123772.pdf | Download (988kB)

| Preview


Background: Globally, cancer is one of the leading causes of mortality. High treatment cost, partly owing to higherprices of anti-cancer drugs, presents a significant burden on patients and healthcare systems. The aim of thepresent study was to survey and compare retail prices of anti-cancer drugs between high, middle and low incomecountries in the South-East Asia, Western Pacific and Eastern Mediterranean regions.Methods: Cross-sectional survey design was used for the present study. Pricing data from ten counties includingone from South-East Asia, two from Western Pacific and seven from Eastern Mediterranean regions were used in thisstudy. Purchasing power parity (PPP)-adjusted mean unit prices for 26 anti-cancer drug presentations (similarpharmaceutical form, strength, and pack size) were used to compare prices of anti-cancer drugs across three regions. Astructured form was used to extract relevant data. Data were entered and analysed using Microsoft Excel®.Results: Overall, Taiwan had the lowest mean unit prices while Oman had the highest prices. Six (23.1%) and nine (34.6%) drug presentations had a mean unit price below US$100 and between US$100 and US$500 respectively. Eightdrug presentations (30.7%) had a mean unit price of more than US$1000 including cabazitaxel with a mean unit priceof $17,304.9/vial. There was a direct relationship between income category of the countries and their mean unit price;low-income countries had lower mean unit prices. The average PPP-adjusted unit prices for countries based on theirincome level were as follows: low middle-income countries (LMICs): US$814.07; high middle income countries (HMICs):US$1150.63; and high income countries (HICs): US$1148.19.Conclusions: There is a great variation in pricing of anticancer drugs in selected countires and within their respectiveregions. These findings will allow policy makers to compare prices of anti-cancer agents with neighbouring countriesand develop policies to ensure accessibility and affordability of anti-cancer drugs.

Item Type: Article
Authors/Creators:Salmasi, S and Lee, KS and Ming, LC and Neoh, CF and Elrggal, ME and Babar, ZD and Khan, TM and Hadi, MA
Keywords: Anti-cancer drugs, Pricing, South-East Asia, Western Pacific, Eastern Mediterranean
Journal or Publication Title: BMC Cancer
Publisher: Biomed Central Ltd
ISSN: 1471-2407
DOI / ID Number: 10.1186/s12885-017-3888-y
Copyright Information:

Copyright 2017 The Authors. Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0)

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page